Pfizer Receives FDA Approval for TALZENNA Combination Therapy

Pfizer said the FDA approved TALZENNA (talazoparib) in combination with XTANDI to treat patients with mAPMN/S prostate cancer harboring HRR gene mutations. TALZENNA is an oral PARP inhibitor that blocks enzymes involved in DNA damage repair. The approval expands treatment options for this patient group and adds to Pfizer’s oncology portfolio; the article reports no financial figures or stock-price impact.